NeuroNasal

NeuroNasal is a San Diego-based specialty pharmaceutical company developing intranasal delivery formulations of psychedelic compounds, including psilocybin and ketamine, for the treatment of psychiatric conditions. The company's core innovation lies in its proprietary nasal delivery technology, which is designed to enhance bioavailability and improve dose precision compared to traditional oral administration routes. By reformulating these compounds for intranasal use, NeuroNasal aims to enable faster onset of therapeutic effects, greater consistency across patient populations, and more controlled clinical dosing environments. This approach addresses longstanding challenges in psychedelic-assisted therapy around pharmacokinetic variability and session management.

NeuroNasal has raised $4 million in seed funding, signaling early investor confidence in both its technology platform and the broader momentum within the psychedelic therapeutics sector. The company is positioned at an early but pivotal stage, translating its delivery science into formulations that can support regulated clinical development pathways. As psychedelic compounds continue to advance through FDA review processes, NeuroNasal's work on optimized delivery mechanisms becomes increasingly relevant to how these therapies are ultimately deployed in clinical and outpatient settings. The company's location in San Diego also places it within a robust biotech ecosystem that supports access to research partnerships, regulatory expertise, and specialized talent.

NeuroNasal represents an important convergence of drug delivery engineering and the rapidly evolving psychedelic medicine landscape, addressing a gap that pure molecule-focused developers often overlook. While much of the industry's attention has centered on the therapeutic compounds themselves, delivery method remains a critical determinant of clinical efficacy, safety, and patient experience. Companies like NeuroNasal that focus on formulation science have the potential to differentiate approved compounds, extend intellectual property positions, and improve real-world treatment outcomes. Their work could ultimately shape how next-generation psychiatric therapies are standardized and scaled across healthcare systems.